Pieter Stolk

Learn More
Since 1977, the WHO Model List of Essential Medicines (EML), published by WHO, has provided advice for Member States that struggle to decide which pharmaceutical technologies should be provided to patients within their public health systems. Originating from outside WHO, an incentive system has been put in place by various governments for the development of(More)
BACKGROUND Meetings are an important way of exchanging scientific information, but full diffusion of new information can only be achieved when results are published in scientific journals. PURPOSE (1) To determine the publication frequency of accepted abstracts for the yearly international conferences on pharmacoepidemiology (ICPE) and to examine(More)
To analyse the consumption of a number of medicines with a known potential for increasing the risk of road traffic accidents in the general population of Europe. Questionnaires were distributed through the European Drug Utilization Research Group (EuroDURG) and Post-Innovation Learning through Life-events of drugs (PILLS) networks. A total of 30 countries(More)
Variation in antihypertensive drug utilization and guideline preferences between six European countries (Denmark, Finland, Germany, Norway, Sweden, the Netherlands) was investigated. Our objectives were to compare between-country variability in utilization per class of antihypertensive agents and to assess guideline preferences in relation to actual use.(More)
The declining productivity of drug research and development (R&D) analysed in an article by Paul and colleagues (How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nature Rev. Drug Discov. 9, 203–214 (2010))1 is of major concern for private and public stakeholders in the pharmaceutical industry, and in health care more broadly.(More)
OBJECTIVES Administration to rats of mood stabilizers approved for bipolar disorder (BD) downregulates markers of the brain arachidonic acid (AA, 20:4n-6) metabolic cascade, including phospholipase A(2) (PLA(2)) and cyclooxygenase (COX) expression. We hypothesized that other agents that target the brain AA cascade, nonsteroidal anti-inflammatory drugs(More)
BACKGROUND Guidance and exploratory evidence indicate that the type of endpoints and the magnitude of their outcome can define a therapy's clinical activity; however, little empirical evidence relates specific endpoint properties with regulatory outcomes. MATERIALS AND METHODS We explored the relationship of 3 endpoint properties to regulatory outcomes by(More)
BACKGROUND COX-2 inhibitors (COX-2i) have been reported to have beneficial effects on schizophrenia. This observational study assesses the association between exposure to COX-2i or/and NSAIDs and schizophrenia deterioration. METHODS We conducted a case-control study within a cohort (n=3,485) of antipsychotic users with a schizophrenia diagnosis(More)
INTRODUCTION AND OBJECTIVE Pharmacovigilance requirements for biologics mandate that EU Member States shall ensure that any biologic that is the subject of a suspected adverse drug reaction (ADR) is identifiable by brand name and batch number. Recent studies showed that brand name identification is well established, whereas batch numbers are (still) poorly(More)